Q&A With Gerald Smetana, MD, from Beth Israel Deaconess Medical Center: Discussing Rivaroxaban's Newest Approvals in Primary Care

Video

Rivaroxaban, also known as Xarelto has been on the market for many years but was recently approved for use in patients with DVT and pulmonary embolism.

Rivaroxaban, also known as Xarelto has been on the market for many years but was recently approved for use in patients with DVT and pulmonary embolism.

Gerald Smetana, MD, from Beth Israel Deaconess Medical Center discussed how the approval can benefit patients during the American College of Physicians Internal Medicine Meeting in Boston. Smetana said one of the main points about the new approval is that unlike warfarin, patients on rivaroxaban do not require monitoring.

Related Videos
Video 2 - "Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment "
Video 1 - "Novel Cardio Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause "
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Noa Krugliak Cleveland, MD | Credit: University of Chicago
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
Ali Rezaie, MD | Credit: X
Should We Reclassify Diabetes Subtypes?
Remo Panaccione, MD | Credit: University of Calgary
Francisca Joly, MD, PhD | Credit: The Transplantation Society
© 2024 MJH Life Sciences

All rights reserved.